Notably, pharmaceutical inhibitors of the ACAT1 (the product of SOAT1 gene), such as CP‐113,818, CI‐1011, K‐604, or F12511 reduced amyloid pathology by lowering neuronal Aβ generation or by enhancing Aβ clearance through upregulated microglial MAMs.70, 71, 72. The gene discussed is SOAT1; the disease is amyloidosis.